Evivo Clinical Trials Summary

Persistence of Supplemented Bifidobacterium longum subsp. infantis EVC001 in Breastfed Infants

Pediatrician with Evivo baby

12/6/2017 — The bacteria in Evivo, Bifidobacterium longum subsp. infantis (B. infantis) is the critically important bacteria in baby’s gut microbiome early in life. It helps to program metabolism and the immune system and supports the complete digestion of nutrients.

Unfortunately, due to generations of modern medical practices such as antibiotics and C-sections, most babies no longer acquire B. infantis  early in life. Without it, potentially harmful bacteria thrive which have been linked to higher risk of colic, eczema, allergies, diabetes, and obesity. To date, probiotics have focused on general gut health and digestion, but until now had not demonstrated the ability to reduce potentially harmful bacteria.

In a controlled clinical trial led by University of California, Davis Medical Center, breastfed babies were given Evivo (activated B. infantis EVC001) once a day and compared to a similar group of babies who did not receive Evivo.  This study showed the first-ever restoration of the baby gut microbiome via Evivo. Babies given Evivo saw a 79% increase in bifidobacteria. These Evivo babies also experienced an unprecedented 80% reduction of groups of potentially harmful bacteria such as E. coli, clostridia, Staphylococcus (Staph), and Streptococcus (Strep), which have been linked to disease later in life.  Finally, across all babies in the study, those high in bifidobacteria had four times lower levels of endotoxin, a compound known to cause inflammation.

In summary, providing Evivo to babies in this clinical study completely restored the naturally protective gut microbiome in 100% of breastfed babies and significantly reduced potentially harmful groups of bacteria compared to babies who didn’t receive Evivo.

To read this article in full:   

 

These data have been presented at major international medical and scientific conferences, and have been published in peer-reviewed journals. Key presentations include:

American Academy of Pediatrics (AAP) 2016

“The Infant Microbiota and Probiotic Intake (IMPRINT) Study: Safety and Tolerability of Consuming Bifidobacterium longum subspecies infantis in Exclusively Breastfed Term Infants”.      

Pediatric Academic Society (PAS) 2017

American Academy of Pediatrics (AAP) 2017

Resources for Professionals

  • Evivo-Safety-20-and-Tolerability
    Evivo™ was safely consumed and well-tolerated in a controlled clinical trial.
    Download PDF
  • Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut
    Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut
    Jump to Article
  • Nature’s first functional food Breast milk feeds helpful microbes, fights harmful ones, provides immunity, and jump-starts a newborn’s life
    Breast milk feeds helpful microbes, fights harmful ones, provides immunity, and jump-starts a newborn’s life
    Download PDF
  • Restoring-Infant-Gut-Microbiome
    97% of babies no longer acquire B.infantis, allowing for potentially harmful bacteria to dominate the gut. Learn more.
    View Video